|Status : Published
|Published On : Dec, 2023
|Report Code : VRHC1279
|Industry : Healthcare
|Available Format :
|Page : 220
Emerging infectious disease diagnostics involves the identification and monitoring of novel pathogens that pose a threat to public health. Utilizing advanced technologies such as PCR, genomics, and immunodiagnostics, it aims to rapidly detect and characterize new infectious agents. This field plays a crucial role in outbreak response, enabling early containment measures and treatment strategies. Continuous surveillance, international collaboration, and the integration of artificial intelligence enhance the ability to swiftly diagnose and understand emerging diseases. By combining molecular biology with innovative diagnostic tools, Emerging Infectious Disease Diagnostics contributes to global efforts in preemptively managing and mitigating the impact of infectious threats on a population's well-being.
Global emerging infectious disease diagnostics market was worth USD 20.20 billion in 2023 and is expected reach USD 32.50 billion by 2030 with a CAGR of 6.44% during the forecast period, i.e., 2025-2030. The growing demand for emerging infectious disease diagnostics is driven by the increasing incidence of novel pathogens, rapid technological advancements in diagnostic tools, heightened awareness due to past pandemics, global surveillance efforts, and the imperative for prompt identification to facilitate timely public health responses.
Geographically, the global emerging infectious disease diagnostics market is expanding rapidly in North America, Europe, and the Asia Pacific, as a result of the robust healthcare infrastructure, advanced diagnostic technologies, proactive government initiatives, heightened awareness post-pandemics, and increasing research investments; however, the market confronts constraints such as regulatory hurdles, limited access to advanced diagnostic technologies in developing regions, resource constraints, and the unpredictable nature of emerging diseases. Overall, the emerging infectious disease diagnostics market offers potential prospects for market participants to develop and fulfill the growing needs of wide range of industries including hospitals and clinics, and diagnostics laboratories.
Insight by Technology
Based on technology, the global emerging infectious disease diagnostics market is segmented into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), immunodiagnostics, and other technologies. Polymerase Chain Reaction (PCR) dominated the global emerging infectious disease diagnostics market in 2022 due to its precision, sensitivity, and rapid results. PCR enables targeted amplification of genetic material for specific pathogen detection. Examples include its pivotal role in diagnosing COVID-19, allowing rapid and accurate identification of the SARS-CoV-2 virus. While isothermal nucleic acid amplification technology (INAAT) offers simplicity, PCR's established track record and widespread adoption make it the current frontrunner. However, the landscape may evolve with ongoing advancements; for instance, Next-Generation Sequencing (NGS) is increasingly utilized for comprehensive genomic analysis in emerging infectious disease research.
Insight by Type of Infection
Based on type of infection, the global emerging infectious disease diagnostics market is segmented into bacterial, viral, fungal, and other infections. Viral infections currently dominate the global emerging infectious disease diagnostics market due to their propensity for rapid transmission and global impact. Notably, the rise of novel viruses, such as the COVID-19 in 2020 and the Zika virus, which emerged in 2015, and the ongoing challenges posed by influenza variants, underscores the need for effective viral diagnostics. These instances highlight the urgency and demand for diagnostics that can swiftly and accurately identify viral pathogens, shaping the market's focus towards viral detection technologies in the ongoing efforts to tackle emerging infectious diseases.
Insight by Disease Type
Based on disease type, the global emerging infectious disease diagnostics market is segmented into respiratory infections, sexually transmitted infections (STIs), gastrointestinal infections, and other infections. Respiratory infections currently dominate the global emerging infectious disease diagnostics market due to their widespread occurrence and significant public health impact. Notably, the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has underscored the critical need for accurate and rapid respiratory diagnostics. With its unprecedented global impact since December 2019, COVID-19 has driven a surge in demand for respiratory diagnostics, emphasizing the urgency for effective tools in managing emerging infectious diseases. This trend is likely to persist as respiratory pathogens continue to pose substantial threats to public health worldwide.
Insight by Application
Based on application, the global emerging infectious disease diagnostics market is segmented into laboratory testing and point-of-care testing. Laboratory testing currently dominate the global emerging infectious disease diagnostics market due to its capacity for high-throughput, comprehensive analysis, and precise identification of pathogens. The significance of labs was evident during the COVID-19 pandemic, where central laboratories played a crucial role. For instance, the widespread use of RT-PCR tests, like the TaqPath COVID-19 Combo Kit, in labs facilitated large-scale testing since its FDA approval in July 2020. The extensive capabilities of labs, coupled with their infrastructure for complex testing procedures, make them essential in managing and understanding emerging infectious diseases, ensuring accurate diagnosis and facilitating effective public health responses.
Insight by End-User
Based on end-user, the global emerging infectious disease diagnostics market is segmented into hospitals and clinics, diagnostics laboratories, and other end-users. Hospitals and clinics dominated the global emerging infectious disease diagnostics market in 2023 due to their role as primary healthcare settings, where timely and accurate diagnostics are pivotal. The COVID-19 pandemic, exemplified by the rapid deployment of diagnostic tests in healthcare facilities globally, underscores this dominance. For instance, the widespread adoption of point-of-care PCR tests in hospitals, like the Xpert Xpress SARS-CoV-2 test, has enabled swift diagnosis since its FDA approval in March 2020. The centralization of diagnostic resources in hospitals and clinics ensures efficient patient management and containment of emerging infectious diseases, solidifying their position in the diagnostics market.
Global Emerging Infectious Disease Diagnostics Market Report Coverage
2018 - 2023
Base Year Considered
2025 - 2030
Market Size in 2023
U.S.D. 20.20 Billion
Revenue Forecast in 2030
U.S.D. 32.50 Billion
Segments Covered in the Report
By Technology, By Type of Infection, By Disease Type, By Application, By End-Use Industry
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report
North America, Europe, Asia-Pacific, Middle East, and South America
Continuous evolution of diagnostic technologies
One major growth driver for the global emerging infectious disease diagnostics market is the continuous evolution of diagnostic technologies, exemplified by recent advancements in CRISPR-based diagnostics. In August 2021, the FDA granted Emergency Use Authorization for Sherlock BioSciences' Sherlock CRISPR SARS-CoV-2 kit, showcasing the potential of CRISPR technology in rapid and specific pathogen detection. CRISPR-based diagnostics offer advantages like high sensitivity, specificity, and potential for multiplexing, revolutionizing infectious disease diagnostics. The adaptability and precision of such technologies contribute significantly to the market's growth, fostering innovation in diagnostic approaches. As these technologies become more accessible and versatile, they are expected to reshape the landscape of emerging infectious disease diagnostics, driving market expansion and improving response capabilities in the face of novel pathogens.
Increasing emphasis on decentralized testing and point-of-care diagnostics
Another major growth driver for the global emerging infectious disease diagnostics market is the increasing emphasis on decentralized testing and point-of-care diagnostics. This shift is evident with the emergence of portable and rapid testing solutions, exemplified by the LumiraDx Platform. In October 2022, LumiraDx received FDA clearance for its SARS-CoV-2 Antigen Test on the LumiraDx Platform, showcasing the trend towards accessible and swift diagnostics. Point-of-care testing reduces turnaround time, enhances patient management, and aids in early containment efforts during outbreaks. The demand for user-friendly, on-site diagnostics, especially in resource-limited settings, is driving innovation in portable technologies, contributing significantly to market growth as healthcare systems globally prioritize decentralized testing for emerging infectious diseases.
Complex regulatory approval process
A major challenge for the global emerging infectious disease diagnostics market is the potential for regulatory complexities and delays in the approval process. Stringent regulatory requirements, varying across regions, can hinder the timely introduction of new diagnostic technologies. For instance, navigating the regulatory landscape for novel diagnostic tests, like those developed during public health emergencies, such as the COVID-19 pandemic, can be intricate. Delays in regulatory approvals may impede the rapid deployment of essential diagnostic tools, impacting the market's responsiveness to emerging infectious threats and hindering the ability to swiftly implement effective diagnostic solutions.
Asia Pacific (APAC)
Middle East and Africa (MEA)
The global emerging infectious disease diagnostics market is segmented into North America, Europe, the Asia-Pacific, South America, and the Middle East and Africa region. The global emerging infectious disease diagnostics market was dominated by North America in 2023 due to its robust healthcare infrastructure, significant research investments, and proactive regulatory environment. Notably, the FDA's swift approvals of diagnostic tools during the COVID-19 pandemic, such as the FDA Emergency Use Authorization for Roche's Elecsys IL-6 test in June 2020, demonstrate the region's ability to efficiently respond to emerging threats. The concentration of major diagnostic companies, research facilities, and a well-established healthcare system enhances North America's position in driving innovation and rapid deployment of advanced diagnostics, consolidating its dominance in the global market.
Abbott Laboratories is a leading player in the global emerging infectious disease diagnostics market, known for its innovative diagnostic solutions. Abbott's ID NOW COVID-19 test, granted Emergency Use Authorization by the FDA in March 2020, exemplifies their commitment to rapid and on-site testing. This molecular test provides results in just minutes, facilitating quick decision-making in healthcare settings. Abbott's global presence and extensive portfolio contribute to its dominance in infectious disease diagnostics, addressing challenges posed by emerging pathogens.
Bio-Rad Laboratories is a key player with a strong focus on infectious disease diagnostics. The company's Bio-Plex 2200 system offers multiplex testing capabilities, allowing simultaneous detection of various pathogens. This technology streamlines the diagnostic process, enhancing efficiency and accuracy. Bio-Rad's commitment to research and development is evident in their BioFire FilmArray system, which enables syndromic testing for a broad range of infectious diseases. These innovative solutions position Bio-Rad as a major influencer in the global emerging infectious disease diagnostics market, addressing the evolving landscape of infectious threats.
Recent Development by Key Players
In November 2023, UK-based Oxford Nanopore Technologies and Boston-based Day Zero Diagnostics announced partnership to develop a rapid diagnostic solution for bloodstream infections. The integrated system aims to provide same-day identification and genomic-based antibiotic susceptibility profiling without the need for blood culture. Leveraging Oxford Nanopore's high-throughput sequencing and Day Zero Diagnostics' AI-driven microbial identification technology, the collaboration seeks regulatory approvals, including from the U.S. FDA.
In November 2023, Oxford Nanopore and Day Zero Diagnostics announced collaboration to create a rapid diagnostic solution for bloodstream infections, a major cause of sepsis. The collaboration aims for same-day identification and genomic-based antibiotic susceptibility profiling, bypassing the need for blood culture. Targeting clinical settings like hospitals, the partnership seeks regulatory approvals, including from the FDA, highlighting the critical need for rapid diagnosis in managing infections and addressing the challenge of antibiotic-resistant strains.
Key Players Covered in the Report
Abbott Laboratories, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories, Inc., Co-Diagnostics, Inc., DANAHER CORPORATION, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Hologic, Inc., QIAGEN N.V., QuidelOrtho Corporation, T2 Biosystems, Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Siemens Healthineers AG.
The emerging infectious disease diagnostics market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.
Segments Covered in the Report
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Next-Generation Sequencing (NGS)
By Type of Infection
By Disease Type
Sexually Transmitted Infections (STIs)
Hospitals and Clinics
Region Covered in the Report
Rest of Europe
Rest of Asia-Pacific
Middle East and Africa (MEA)
Rest of MEA
Rest of South America